EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Boehringer Ingelheim partnered with Inflammasome Therapeutics to develop up to three retinal disease therapies. The candidates will use Inflammasome’s intravitreal delivery technologies to get Boehringer molecules to retinal targets. Statement 

> GenSight Biologics shared more data on its Leber hereditary optic neuropathy gene therapy. The biotech plans to file for approval in Europe in the third quarter of 2020. Release 

> Tacalyx raised €7 million ($7.7 million) to generate anti-tumor associated carbohydrate antigen cancer therapies. Boehringer Ingelheim Venture Fund and Kurma Partners co-led the round. Statement 

> Kadimastem shared data from a phase 1/2a trial of its cell therapy in amyotrophic lateral sclerosis. Release 

> T3 Pharmaceuticals raised CHF 12 million (€11 million) to move its lead drug into the clinic next year. The candidate is a bacterium engineered to grow and produce therapeutic proteins in solid tumors. Statement 

> The FDA set a late February PDUFA date for Acacia Pharma’s Barhemsys. Release 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.